Sutro Biopharma (NASDAQ:STRO) Stock Rating Lowered by Citizens Jmp

Sutro Biopharma (NASDAQ:STRO - Get Free Report) was downgraded by equities researchers at Citizens Jmp from an "outperform" rating to a "market perform" rating in a note issued to investors on Friday, MarketBeat reports.

A number of other brokerages have also recently issued reports on STRO. Bank of America cut shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and dropped their price objective for the company from $11.00 to $1.00 in a research note on Friday. Wells Fargo & Company cut their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 11th. Wedbush downgraded Sutro Biopharma from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $8.00 to $2.00 in a report on Friday. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $6.63.

Remove Ads

Sutro Biopharma Trading Down 3.9 %

STRO stock traded down $0.04 during trading on Friday, reaching $0.90. 2,353,555 shares of the stock were exchanged, compared to its average volume of 961,786. The stock has a 50 day simple moving average of $1.73 and a 200-day simple moving average of $2.70. The company has a market capitalization of $73.89 million, a P/E ratio of -0.56 and a beta of 1.22. Sutro Biopharma has a twelve month low of $0.76 and a twelve month high of $6.13.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The firm had revenue of $14.00 million for the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. During the same period in the previous year, the business posted ($1.78) EPS. Equities analysts predict that Sutro Biopharma will post -2.92 EPS for the current year.

Institutional Trading of Sutro Biopharma

Several large investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new position in shares of Sutro Biopharma in the fourth quarter valued at about $26,000. Gladius Capital Management LP acquired a new stake in Sutro Biopharma in the 3rd quarter valued at about $28,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Sutro Biopharma in the fourth quarter worth about $32,000. Vontobel Holding Ltd. lifted its position in shares of Sutro Biopharma by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $46,000 after purchasing an additional 10,000 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Sutro Biopharma by 74.3% during the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock valued at $50,000 after purchasing an additional 11,494 shares during the last quarter. Institutional investors own 96.99% of the company's stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.